Michael Alonso Email & Phone Number

Santa Clara, Ca, Us

Redwood City, California, Us

Redwood City, California, Us

Redwood City, California, Us

We set out to develop novel immunotherapeutics designed to eliminate metastatic disease based on groundbreaking technology from Stanford University that we published in Nature, Cell and JCI insight. These studies demonstrated that simultaneous delivery of anti-tumor antibody and immune adjuvant elicits powerful anti-tumor immunity that eliminates primary tumors and metastatic disease. We subsequently discovered that covalent attachment of an immune stimulant to an anti-tumor antibody dramatically increased anti-tumor immunity and could be delivered as a single Boltbody therapeutic.We filed IP, raised the Series A and set up the framework needed to select a lead for clinical development.

Palo Alto, Ca, Us

My studies at Stanford University utilized bioinformatics technology to better understand the cellular distribution of complex tissues. We actively pursued mechanisms that governed the formation of tolerogenic dendritic cell subsets and strategies for converting immunosuppressive dendritic cells into proinflammatory dendritic cells capable of eliciting robust anti-tumor immunity.As a manager, I supervised a 22 member laboratory with Dr. Engleman and helped define our experimental and regulatory strategies. I also participated in personnel decisions, wrote grants, edited manuscripts and ensured the compliance of our laboratory with all University, State and Federal regulations.

Organ-i presented an exciting opportunity to leverage my expertise to develop and commercialize several renal transplant diagnostic products. I was responsible for overseeing the product development roadmap and coordinating with our legal team to ensure a robust patent portfolio. I also managed relationships with consultants and collaborations with leading academic and industry partners. These responsibilities included the presentation of results to CEO’s and VP’s of Research at leading Biotechnology firms. Lastly, I jointly identified a small set of serum biomarkers that distinguish chronic rejection from acute rejection with Dr. Sigdel. I am proud to say that renal transplant patients should benefit from our efforts in the near future.

Stanford, Ca, Us

My research at Stanford demonstrated that activated T cells dictate the nature of the immune response by instructing monocytes to differentiate into specialized dendritic cell subsets. We defined this pathway during psoriasis, atopic dermatitis and transplant rejection. We also defined several strategies to deplete inflammatory dendritic cells and achieve immune quiescence. Mentor: Edgar Engleman

Champaign, Il, Us

My studies in Dr. Greenough's laboratory pioneered the feasibility of delivering gene therapy to Fragile X patients in preclinical models. While the delivery was successful, the mice mounted an immune response against the newly translated protein that limited the effectiveness of genetic therapy. As such, I went to Stanford University to expand my knowledge of the body's immune system.

Champaign, Il, Us

Evaluated the effectiveness of fungicides on a devastating fungus linked to the Irish Potato Famine in Dr. Mohammad Babadoost's laboratory. These studies uncovered several candidates for the elimination of Phytophthora Blight.

Phd, Immunology

Institute For Entrepreneurship

B.S., Molecular And Cellular Biology